JB Chemicals & Pharmaceuticals Ltd (JB Pharma), one of the fastest growing pharmaceutical companies in India, announced its financial results for the quarter ended 31st December 2025.

The company recorded revenue of Rs. 1,065 crore in the third quarter of FY26, registering growth of 11 per cent from Rs. 963 crore in Q3 FY25. Operating EBITDA (Earnings before Interest, Depreciation and Taxes) increased by 13 per cent to Rs. 305 crore compared to Rs. 270 crore in the same quarter last year. Net Profit rose by 22 per cent to Rs. 198 crore as compared to Rs. 162 crore in Q3 FY25.

Commenting on the financial results, Nikhil Chopra, CEO and Wholetime Director, JB Pharma stated "JB Pharma's domestic formulations business, once again outperformed the Indian pharmaceutical market, driven by broad-based momentum across key chronic therapies and continued strength in our flagship brands. On the international front, while the CDMO business continued its positive momentum, the international formulations business also recorded strong growth in several key markets.

Our focus on cost optimization, favourable product mix and operational efficiencies led to improved operating margins for Q3 FY26 as well as for 9M FY26. With a strong balance sheet, net cash position, and sustained cash flow generation, we remain confident in our ability to deliver profitable growth. As we move forward, our priorities remain centered on strengthening flagship brand franchises, accelerating growth in chronic therapies, scaling our CDMO businesses, and building a resilient, agile, and future-ready organization."

For the first nine months of the financial year 2025-26, the company recorded revenue of Rs. 3,244 crore as compared to Rs. 2,969 crore, registering growth of 9 per cent. Operating EBITDA (Earnings Before Interest Depreciation and Taxes) increased by 13 per cent to Rs. 955 crore as compared to Rs. 846 crore. Profit after Tax registered growth of 18 per cent to Rs. 608 crore in 9M FY26 as compared to Rs. 514 crores in 9M FY25.